轉移病灶切除對於轉移性腎臟癌的效應----臺中榮總經驗
李建儀、楊晨洸1、楊啟瑞2、歐宴泉1
臺中榮民總醫院 外科部 泌尿外科；1中國醫藥大學附設醫院 泌尿部，2
Impact of metastasectomy on metastatic renal cell carcinoma treatment---experience of taichung veterans general hospital
Jian-Ri Li, Cheng-Kuang Yang1, Chi-Rei Yang2, Yen-Chuan Ou
Divisions of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Urology1, China Medical University Hospital, Taichung, Taiwan
Purpose: We reported our experience in conducting metastasectomy in metastatic renal cell carcinoma (mRCC) and analyzed the clinical benefit.
Materials and Methods: Between 2005 and 2016, we retrospectively collected 131 patients patients who received targeted therapy. Seven patients were excluded because of inadequate data collection and follow-up. Among 124 included patients, 49(39.5%) received metastasectomy. The patient characteristics and overall survival were analyzed. Cox regression was used for variable analysis.
Results: Metastasectomy group had more percentage of favorable or intermediate Memorial Sloan Kettering Cancer Center risk group (98% vs. 77.3%, p=0.003). Median targeted treatment duration, follow-up duration and estimated overall survival were longer in the metastasectomy group. In subgroup analysis, metastasectomy group patients who survived in this study showed less targeted therapy item use and longer targeted treatment duration.
Conclusions: Metastasectomy could be considered benefit in overall survival in selective patients. The most relevant impact of metastasectomy is reduction of targeted regimen item use.